Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul G Corn

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Cancers|April 3, 2021
Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate CancerAnna S Gerdtsson, Sonia M Setayesh, Paymaneh D Malihi, et al.
Prostate Cancer and Prostatic Diseases|September 17, 2024
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancerAndrew M Fang, Brian F Chapin, Charles W Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate CancerZhe Tang, Patrick G Pilié, Chuandong Geng, et al.
Cancer|August 27, 2014
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancerMehmet Asim Bilen, Marcella M Johnson, Paul Mathew, et al.
Cancer Research Communications|November 6, 2023
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate CancerEmanuela Gentile, Andrew W Hahn, Jian H Song, et al.
Cancer Chemotherapy and Pharmacology|July 22, 2017
Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapyMehmet Asim Bilen, Kenneth R Hess, Sumit K Subudhi, et al.
Journal for Immunotherapy of Cancer|October 19, 2021
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironmentSumit K Subudhi, Bilal A Siddiqui, Ana M Aparicio, et al.
Cancer Research|July 8, 2022
Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast TransitionGuoyu Yu, Paul G Corn, Pengfei Shen, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2024
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancerRyan E Fecteau, Bridget F Koontz, Karen E Hoffman, et al.
Clinical Genitourinary Cancer|February 21, 2017
Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy EraSarathi Kalra, Jonathan Verma, Bradley J Atkinson, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Cancers|April 3, 2021
Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate CancerAnna S Gerdtsson, Sonia M Setayesh, Paymaneh D Malihi, et al.
Prostate Cancer and Prostatic Diseases|September 17, 2024
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancerAndrew M Fang, Brian F Chapin, Charles W Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate CancerZhe Tang, Patrick G Pilié, Chuandong Geng, et al.
Cancer|August 27, 2014
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancerMehmet Asim Bilen, Marcella M Johnson, Paul Mathew, et al.
Cancer Research Communications|November 6, 2023
Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate CancerEmanuela Gentile, Andrew W Hahn, Jian H Song, et al.
Cancer Chemotherapy and Pharmacology|July 22, 2017
Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapyMehmet Asim Bilen, Kenneth R Hess, Sumit K Subudhi, et al.
Journal for Immunotherapy of Cancer|October 19, 2021
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironmentSumit K Subudhi, Bilal A Siddiqui, Ana M Aparicio, et al.
Cancer Research|July 8, 2022
Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast TransitionGuoyu Yu, Paul G Corn, Pengfei Shen, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2024
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancerRyan E Fecteau, Bridget F Koontz, Karen E Hoffman, et al.
Clinical Genitourinary Cancer|February 21, 2017
Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy EraSarathi Kalra, Jonathan Verma, Bradley J Atkinson, et al.
Pageof 10